Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 2, 2012, Pages 317-325

  Dos Santos Ferreira, Ana Carolina ^a   Fernandes, Renan Amphilophio ^a   Kwee, Jolie Kiemlian ^a   Klumb, Claudete Esteves ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Apoptosis; Bim protein; Burkitt's lymphoma; Chemotherapy; Histone deacetylase inhibitor

Indexed keywords

BIM PROTEIN; BUTYRIC ACID; CASPASE 3; CASPASE 9; CISPLATIN; ETOPOSIDE; HISTONE DEACETYLASE INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1;

APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOMA CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; BURKITT LYMPHOMA; BUTYRATES; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SYNERGISM; ETOPOSIDE; HISTONE DEACETYLASE INHIBITORS; HUMANS; MEMBRANE PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; UP-REGULATION;

EID: 84857035938     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1093-y     Document Type: Article

References (48)

1. Aldoss IT, Weisenburger DD, Fu K, Chan WC, Vose JM, Bierman PJ, Bociek RG, Armitage JO (2008) Adult Burkitt lymphoma: advances in diagnosis and treatment. Oncology 22: 1508-1517
2. Atra A, Gerrard M, Hobson R, Imeson JD, Hann IM, Pinkerton CR (2001) Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols. Br J Haematol 112: 965-968. doi: 10.1046/j.1365-2141.2001.02647.x (Pubitemid 32322922)
3. Belloc F, Belaud-Rotureau MA, Lavignolle V, Bascans E, Braz-PereiraE, Durrieu F, Lacombe F (2000) Flow cytometry detection of caspase 3 activation in preapoptotic leukemic cells. Cytometry 40: 150-151. doi: 10.1002/(SICI)1097- 0320(20000601)40: 2\151: AID-CYTO9[3.0.CO;2-9
4. Bornkamm GW (2009) Epstein-Barr virus and its role in the pathogenesis of Burkitt's lymphoma: an unresolved issue. Semin Cancer Biol 19: 351-365. doi: 10.1016/j.semcancer.2009.07.002
5. Burkitt D (1958) A sarcoma involving the jaws in African children. Br J Surg 46: 218-223
6. Cairo MS, Sposto R, Perkins SL, Meadows AT, Hoover-Regan ML, Anderson JR, Siegel SE, Lones MA, Tedeschi-Blok N, Kadin ME, Kjeldsberg CR, Wilson JF, Sanger W, Morris E, Krailo MD, Finlay JL (2003) Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the children's cancer group experience. Br J Haematol 120: 660-670 (Pubitemid 36255868)
7. Calender A, Billaud M, Aubry JP, Banchereau J, Vuillaume M, Lenoir GM (1987) Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBVnegative B-lymphoma cells. Proc Natl Acad Sci USA 84: 8060-8064 (Pubitemid 18094057)
8. Cang S, Ma Y, Liu D (2009) New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J Hematol Oncol 2: 22-32. doi: 10.1186/1756-8722-2-22
9. Carew JS, Giles FJ, Nawrocki ST (2008) Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 269: 7-17. doi: 10.1016/j.canlet.2008. 03.037
10. Chen X, Wong P, Radany E, Wong JY (2009) HDAC Inhibitor, Valproic acid, induces p53-dependent radiosensitization of colon cancer cells. Cancer Biother Radiopharm 24: 689-699. doi: 10.1089/cbr.2009.0629
11. Cherney BW, Bhatia KG, Sgadari C, Gutierrez MI, Mostowski H, Pike SE, Gupta G, Magrath IT, Tosato G (1997) Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells. Cancer Res 57: 2508-2515 (Pubitemid 27255914)
12. Chou T, Talalay P (1984) Quantitative analysis of dose-effects relationships: the combined effects of multiple drugs or enzyme inhibtors. Adv Enzyme Regul 22: 27-55
13. Craig RW (2002) MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 16: 444-454. doi: 10.1038/sj/leu/2402416 (Pubitemid 34449724)
14. Czabotar PE, Colman PM, Huang DC (2009) Bax activation by Bim? Cell Death Differ 16: 1187-1191. doi: 10.1038/cdd.2009.83
15. Ellis L, Pili R (2010) Histone deacetylase inhibitors: advancing therapeutic strategies in hematological and solid malignancies. Pharmaceuticals (Basel) 3: 2411-2469. doi: 10.3390/ph3082441
16. Ellis L, Bots M, Lindemann RK, Bolden JE, Newbold A, Cluse LA, Scott CL, Strasser A, Atadja P, Lowe SW, Johnstone RW (2009) The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood 114: 380-393. doi: 10.1182/blood-2008-10-182758
17. Emanuele S, Lauricella M, Tesoriere G (2008) Histone deacetylase inhibitors: apoptotic effects and clinical implications Int J Oncol 33: 637-646. doi: 10.3892/ijo-00000049
18. Fischel J-L, Formento P, Milano G (2005) Epidermal growth factorreceptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors Br J Cancer 92: 1063-1068. doi: 10.1038/sj.bjc.6602428 (Pubitemid 40546670)
19. Gerrard M, Cairo MS, Weston C, Auperin A, Pinkerton R, Lambilliote A, Sposto R, McCarthy K, Lacombe MJ, Perkins SL, Patte C (2008) FAB LMB96 International Study Committee. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Br J Haematol 141: 840-847. doi: 10.1111/ j.1365-2141.2008.07144.x (Pubitemid 351724873)
20. Griffin TC, Weitzman S, Weinstein H, Chang M, Cairo M, Hutchison R, Shiramizu B, Wiley J, Woods D, Barnich M, Gross TG, Group Children'sOncology (2009) A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20?) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 52: 177-181. doi: 10.1002/pbc.21753
21. Guo F, Sigua C, Tao J, Bali P, George P, Li Y, Wittmann S, Moscinski L, Atadja P, Bhalla K (2004) Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 64: 2580-2589. doi: 10.1158/ 0008-5472 (Pubitemid 38523916)
22. JazirehiAR(2010) Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy. Anticancer Drugs 21: 805-813. doi: 10.1097/CAD.0b013e32833dad91
23. Kelly GL, Rickinson AB (2007) Burkitt lymphoma: revisiting the pathogenesis of a virus-associated malignancy. Hematology 20: 277-284, http: //asheducationbook. hematologylibrary.org
24. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR, Newmeyer DD (2005) BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Molecular Cell 17: 525-535. doi: 10.1016/j.molcel.2005.02.003 (Pubitemid 40269117)
25. Lemoine M, Younes A (2010) Histone deacetylase inhibitors in the treatment of lymphoma. Discov Med 10: 462-470
26. Magrath I, Jain V, Bhatia K (1982) Epstein-Barr virus and Burkitt's lymphoma. Semin Cancer Biol 3: 285-295
27. Martînez-Iglesias O, Ruiz-Llorente L, Sánchez-Martînez R, Garcîa L, Zambrano A, Aranda A (2008) Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clin Transl Oncol 10: 395-398
28. Mellert HS, Stanek TJ, Sykes SM, Rauscher FJ, Schultz DC, McMahon SB (2011) Deacetylation of the DNA-binding domain regulates p53-mediated apoptosis. J Biol Chem 286: 4264-4270. doi: 10.1074/jbc.M110.184663
29. Mercurio C, Minucci S, Pelicci PG (2010) Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res 62: 18-34. doi: 10.1016/j.phrs.2010.02.010
30. Mêrino D, Giam M, Hughes PD, Siggs OM, Heger K, O'Reilly LA, Adams JM, Strasser A, Lee EF, Fairlie WD, Bouillet P (2009) The role of BH3-only protein Bim extends beyond inhibiting Bcl-2-like prosurvival proteins. J Cell Biol 186: 355-362. doi: 10.1083/jcb.200905153
31. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and citotoxicity assays. J Immunol Methods 65: 55-63. doi: 10.1016/0022-1759(83) 90303-4 (Pubitemid 14203433)
32. Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F, Wang X(2003) Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 17: 1475-1486. doi: 10.1101/gad.1093903 (Pubitemid 36734705)
33. O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, Zelenetz AD, Frankel S, Richon V, Marks P, Kelly WK (2006) Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24: 166-173. doi: 10.1200/JCO.2005. 01.9679 (Pubitemid 46630509)
34. Oriol A, Ribera JM, Bergua J, Gimênez MesaE, Grande C, Esteve J, Brunet S, Moreno MJ, Escoda L, Hernandez-Rivas JM, Hoelzer D (2008) High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer 113: 117-125. doi: 10.1002/cncr.23522 (Pubitemid 351976392)
35. Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, Cairo MS (2007) FAB/LMB96 International Study Committee. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 109: 2773-2780. doi: 10.1182/blood-2006-07- 036673 (Pubitemid 46482070)
36. Richter-Larrea JA, Robles EF, Fresquet V, Beltran E, Rullan AJ, Agirre X, Calasanz MJ, Panizo C, Richter JA, Hernandez JM, Roman-Gomez J, Prosper F, Martinez-Climent JA (2010) Reversion of epigenetically mediated Bim silencing overcomes chemoresistance in Burkitt lymphoma. Blood 116: 2531-2542. doi: 10.1182/blood-2010-02-268003
37. Rosato R, Maggio SC, Almenara JA, Payne SG, Atadja P, Spiegel S, Dent P, Grant S (2006) The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Mol Pharmacol 69: 216-225. doi: 10.1124/mol.105.017145 (Pubitemid 43048908)
38. Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, Koeffler HP (2005) Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 33: 53-61. doi: 10.1016/j.exphem.2004. 09.008 (Pubitemid 40127644)
39. Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM, Garcia-Vargas J, Sanz-Rodriguez C, Rizvi S (2009) Vorinostat in solid and hematologic malignancies. J Hematol Oncol 2: 31-41. doi: 10.1186/1756-8722-2-31
40. Silva KL, Vasconcellos DV, Castro EDP, Coelho AM, Linden R, Maia RC (2006) Apoptotic effect of fludarabine is independent of expression of IAPs in B-cell chronic lymphocytic leukaemia. Apoptosis 11: 277-285. doi: 10.1007/s10495-006-3560-5 (Pubitemid 43291027)
41. Tan J, Cang S, Ma Y, Petrillo RL, Liu D (2010) Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 4: 3-5. doi: 10.1186/1756-8722-3-5
42. Thorley-Lawson DA, Allday MJ (2008) The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nat Rev Microbiol 6: 913-924. doi: 10.1038/nrmicro2015
43. Vayssade M, Haddada H, Faridoni-Laurens L, Tourpin S, Valent A, Bênard J, Ahomadegbe JC (2005) P73 functionally replaces p53 in Adriamycin-treated, p53-deficient breast cancer cells. Int JCancer 116: 860-869. doi: 10.1002/ijc.21033 (Pubitemid 41209191)
44. Walkinshaw DR, Yang XJ (2008) Histone deacetylase inhibitors as novel anticancer therapeutics. Curr Oncol 15: 237-243
45. Wang S, Yan-Neale Y, Cai R, Alimov I, Cohen D (2006) Activation of mitochondrial pathway is crucial for tumor selective induction of apoptosis by LAQ824. Cell Cycle 5: 1662-1668. doi: 10.4161/cc.5.15.3099 (Pubitemid 44285253)
46. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ (2001) Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292: 727-730. doi: 10.1126/science.1059108 (Pubitemid 32385543)
47. Xu WS, Parmigiani R, Marks PA (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552. doi: 10.1038/sj.onc.1210620 (Pubitemid 47255934)
48. Youle J, Strasser A (2008) The Bcl-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59. doi: 10.1038/nrm2308